Fragment-based drug discovery and molecular docking in drug design.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Pharmaceutical Biotechnology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.2174/1389201015666141122204532PMID 25420726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.

  2015cited by this paper
• Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity

  2014cited by this paper
• A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases

  2014cited by this paper
• NMR-based analysis of protein–ligand interactions

  2014cited by this paper
• Fragment-Based Lead Discovery and Design

  2014cited by this paper
• Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase.

  2014cited by this paper
• Computational Methods in Drug Discovery

  2014cited by this paper
• Current and emerging opportunities for molecular simulations in structure-based drug design

  2014cited by this paper
• Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.

  2014cited by this paper
• Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

  2014cited by this paper
• Determination of protein-ligand binding constants of a cooperatively regulated tetrameric enzyme using electrospray mass spectrometry.

  2014cited by this paper
• Design, synthesis and characterization of novel inhibitors against mycobacterial β-ketoacyl CoA reductase FabG4.

  2014cited by this paper
• Molecular similarity in medicinal chemistry.

  2014cited by this paper
• Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.

  2014cited by this paper
• Nanoelectrospray ionization mass spectrometric study of Mycobacterium tuberculosis CYP121-ligand interactions.

  2013cited by this paper
• De novo fragment design: a medicinal chemistry approach to fragment-based lead generation.

  2013cited by this paper
• Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.

  2013cited by this paper
• Identification of inhibitors of the antibiotic-resistance target New Delhi metallo-β-lactamase 1 by both nanoelectrospray ionization mass spectrometry and ultrafiltration liquid chromatography/mass spectrometry approaches.

  2013cited by this paper
• Protein crystallography and fragment-based drug design.

  2013cited by this paper
• Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.

  2013cited by this paper
• Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery

  2013cited by this paper
• The 'rule of three' for fragment-based drug discovery: where are we now?

  2013cited by this paper
• Selectively dispersed isotope labeling for protein structure determination by magic angle spinning NMR

  2013cited by this paper
• Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.

  2013cited by this paper
• Discovery of potent, selective chymase inhibitors via fragment linking strategies.

  2013cited by this paper
• Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.

  2013cited by this paper
• Fragment‐Based Design of Novel Quinazolinon Derivatives as Human Acrosin Inhibitors

  2013cited by this paper
• Application of Bio-Layer Interferometry for the analysis of protein/liposome interactions.

  2013cited by this paper
• Quantifying carbohydrate-protein interactions by electrospray ionization mass spectrometry analysis.

  2012cited by this paper
• Ligand–receptor interaction platforms and their applications for drug discovery

  2012cited by this paper
• Bioactive secondary metabolites from marine microbes for drug discovery.

  2012cited by this paper
• Computer-aided drug design: lead discovery and optimization.

  2012cited by this paper
• Rapid-access, high-throughput synchrotron crystallography for drug discovery.

  2012cited by this paper
• Thermodynamic studies for drug design and screening

  2012cited by this paper
• Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.

  2012cited by this paper
• Introduction to fragment-based drug discovery.

  2012cited by this paper
• Automated protein-ligand interaction screening by mass spectrometry.

  2012cited by this paper
• Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.

  2011cited by this paper
• Molecular docking: a powerful approach for structure-based drug discovery.

  2011cited by this paper
• Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis.

  2011cited by this paper
• Biosensor-based small molecule fragment screening with biolayer interferometry

  2011cited by this paper
• Drug resistance: challenges to effective therapy.

  2011cited by this paper
• Compound Design by Fragment‐Linking

  2011cited by this paper
• Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.

  2010cited by this paper
• Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase.

  2010cited by this paper
• Discovery of a Novel Hsp90 Inhibitor by Fragment Linking

  2010cited by this paper
• Development of an ultrafiltration-liquid chromatography/mass spectrometry (UF-LC/MS) based ligand-binding assay and an LC/MS based functional assay for Mycobacterium tuberculosis shikimate kinase.

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• PI3Kα Inhibitors That Inhibit Metastasis

  2010cited by this paper
• Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.

  2010cited by this paper
• Kinetic analysis and fragment screening with Fujifilm AP-3000.

  2010cited by this paper
• Higher throughput calorimetry: opportunities, approaches and challenges.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

  2010cited by this paper
• Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB.

  2010cited by this paper
• Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy

  2009cited by this paper
• Grading the commercial optical biosensor literature—Class of 2008: ‘The Mighty Binders’

  2009cited by this paper
• Molecular docking and ligand specificity in fragment-based inhibitor discovery.

  2009cited by this paper
• The rise of fragment-based drug discovery.

  2009cited by this paper
• Structural artifacts in protein-ligand X-ray structures: implications for the development of docking scoring functions.

  2009cited by this paper
• Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

  2008cited by this paper
• Generation of a set of simple, interpretable ADMET rules of thumb.

  2008cited by this paper
• Natural products as leads to potential drugs: an old process or the new hope for drug discovery?

  2008cited by this paper
• Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

  2008cited by this paper
• High throughput solubility determination with application to selection of compounds for fragment screening.

  2008cited by this paper
• Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library.

  2008cited by this paper
• Limitations and lessons in the use of X-ray structural information in drug design

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Fragment-based screening using X-ray crystallography and NMR spectroscopy.

  2007cited by this paper
• Integration of fragment screening and library design.

  2007cited by this paper
• Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail

  2007cited by this paper
• Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

  2007cited by this paper
• The influence of drug-like concepts on decision-making in medicinal chemistry

  2007cited by this paper
• Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints

  2007cited by this paper
• Natural products as a screening resource.

  2007cited by this paper
• Virtual ligand screening: strategies, perspectives and limitations

  2006cited by this paper
• Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.

  2006cited by this paper
• Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes

  2006cited by this paper
• Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

  2006cited by this paper
• Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid

  2006cited by this paper
• On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors

  2006cited by this paper
• SAR by ILOEs: an NMR-based approach to reverse chemical genetics.

  2006cited by this paper
• Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

  2006cited by this paper
• TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery.

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• Fragment-based lead discovery using X-ray crystallography.

  2005cited by this paper
• High-throughput drug discovery: what can we expect from HTS?

  2005cited by this paper
• Library design for fragment based screening.

  2005cited by this paper
• Utility of homology models in the drug discovery process

  2004cited by this paper
• The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.

  2004cited by this paper
• Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

  2004cited by this paper
• Determination of dissociation constants for protein-ligand complexes by electrospray ionization mass spectrometry.

  2004cited by this paper
• A 'rule of three' for fragment-based lead discovery?

  2003cited by this paper
• Implications of protein flexibility for drug discovery

  2003cited by this paper
• NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.

  2002cited by this paper
• Principles of docking: An overview of search algorithms and a guide to scoring functions

  2002cited by this paper
• High-throughput crystallography for lead discovery in drug design

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy.

  1999cited by this paper
• Discovering High-Affinity Ligands for Proteins: SAR by NMR

  1996cited by this paper

• N-Acylhydrazones: applications and advances in drug discovery

  2025cites this paper
• Identification of Potential Therapeutic Targets for Sensorineural Hearing Loss and Evaluation of Drug Development Potential Using Mendelian Randomization Analysis

  2025cites this paper
• The Identification and Analysis of Novel Umami Peptides in Lager Beer and Their Multidimensional Effects on the Sensory Attributes of the Beer Body

  2025cites this paper
• Recent progress in the development of small molecule pyruvate kinase M2 inhibitors: 2020-2025.

  2025cites this paper
• Boosting Drug Discovery: Expanding the Applicability of Fragment Dissolved Molecular Dynamics to Accelerate Binding Mode Elucidation

  2025cites this paper
• Molecular Docking in Drug Discovery: Techniques, Applications, and Advancements.

  2024cites this paper
• In Silico methods for the study of the interactions between drugs and their protein targets

  2024cites this paper
• Design, Synthesis, Docking Study of Pyrazolohydrazinopyrimidin‐4‐one Derivatives and Their Application as Antimicrobials

  2023cites this paper
• TWN-FS method: A novel fragment screening method for drug discovery

  2023cites this paper
• Fragment-based virtual screening discovers potential new Plasmodium PI4KIIIβ ligands

  2022cites this paper
• Best Practices for Docking-Based Virtual Screening

  2021cites this paper
• Identification of Novel Inhibitors of Type-I Mycobacterium Tuberculosis Fatty Acid Synthase Using Docking-Based Virtual Screening and Molecular Dynamics Simulation

  2021cites this paper
• Design, Synthesis, and Herbicidal Activity of Thioether Containing 1,2,4-Triazole Schiff Bases as Transketolase Inhibitors.

  2021cites this paper
• In silico methods and tools for drug discovery

  2021cites this paper
• Introductory Chapter: The Emerging Corner of the Omics Studies for Rational Drug Design

  2021cites this paper
• CHARMM-GUI Ligand Designer for Template-Based Virtual Ligand Design in a Binding Site

  2021cites this paper
• Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity

  2021cites this paper
• Identification of Novel Inhibitors of Type-I Mycobacterium Tuberculosis Fatty Acid Synthase Using Docking-Based Virtual Screening and Molecular Dynamics Simulation

  2021cites this paper
• Recent advance on PTP1B inhibitors and their biomedical applications.

  2020cites this paper
• Structure-Based Virtual Screening: From Classical to Artificial Intelligence

  2020cites this paper
• LigBuilder V3: A Multi-Target de novo Drug Design Approach

  2020cites this paper
• Circumstantial Overdose Management of an Efficient Cancer Cell Photosensitizer with Preclinical Evidence: A Biophysical Study.

  2020cites this paper
• Plant systemic acquired resistance compound salicylic acid as a potent inhibitor against SCF (SKP1-CUL1-F-box protein) mediated complex in Fusarium oxysporum by homology modeling and molecular dynamics simulations

  2020influential citation
• Application of Fragment-Based Drug Discovery to Versatile Targets

  2020cites this paper
• In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

  2020cites this paper
• Combined strategies in structure-based virtual screening.

  2020cites this paper
• A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery

  2020cites this paper
• In silico studies on anti-stress compounds of ethanolic root extract of Hemidesmus indicus L.

  2019cites this paper
• Protein Docking and Drug Design

  2019cites this paper
• Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.

  2019cites this paper
• A Practical Perspective: The Effect of Ligand Conformers on the Negative Image-Based Screening

  2019cites this paper
• Discovery of a Novel Series of Tricyclic Oxadiazine 4a-Methyl Esters Based on Indoxacarb as Potential Sodium Channel Blocker/Modulator Insecticides.

  2019cites this paper
• Isolation, bioassay development and applications of tyrosine hydroxylase

  2019cites this paper
• Concepts and Core Principles of Fragment-Based Drug Design

  2019cites this paper
• In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery

  2018cites this paper
• Multitarget Drug Design for Neurodegenerative Diseases

  2018cites this paper
• Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors

  2017cites this paper
• Fragment-Based Drug Design: Strategic Advances and Lessons Learned

  2017cites this paper
• Biofocussed chemoprospecting: An efficient approach for drug discovery

  2017cites this paper
• From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.

  2017cites this paper
• Enthalpy-Based Screening of Focused Combinatorial Libraries for the Identification of Potent and Selective Ligands.

  2017cites this paper
• NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.

  2017cites this paper
• The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches

  2017cites this paper
• High‐Throughput Screening (HTS) by NMR Guided Identification of Novel Agents Targeting the Protein Docking Domain of YopH

  2016cites this paper
• HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study.

  2016cites this paper
• Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs

  2016cites this paper
• Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies

  2016cites this paper
• Biochemical and drug targeting studies of Mycobacterium tuberculosis cholesterol oxidase P450 enzymes

  2016cites this paper
• The Comparison of Docking Search Algorithms and Scoring Functions: An Overview and Case Studies

  2016cites this paper
• Synthesis and biological activity of novel N-(3-furan-2-yl-1-phenyl-1H-pyrazol-5-yl) amides derivatives

  2016cites this paper
• In silico design of high-affinity ligands for the immobilization of inulinase

  2016cites this paper
• Selective Modulators of α5-Containing GABAA Receptors and their Therapeutic Significance.

  2015cites this paper
• Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

  2015cites this paper
• Computational allosteric ligand binding site identification on Ras proteins.

  2015influential citation
• Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.

  2015cites this paper
• Crystal shape engineering of anatase TiO2 and its biomedical applications

  2015cites this paper